Clinical Trial Update: A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (DAYBreak CLL-201) evaluating NX-5948 in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• NX-5948

Snippet

Sponsor: Nurix Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Status: RECRUITING